Skip to main content

Paired Ends: Jan 12, 2010


Zachary Zimmerman had been appointed as director of business development at Regulus Therapeutics, a Carlsbad, Calif.-based company that develops microRNA drugs.

Prior to joining Regulus, he spent five years in the business development group of Alnylam Pharmaceuticals. Before that, he was a senior research analyst for IDC's Life Sciences practice with a focus on disruptive technologies, and prior to that, a lead scientist at 454 Life Sciences.

Zimmerman holds a PhD in molecular, cellular, and developmental biology from the University of California, Santa Cruz.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.